EntreMed announces changes to board of directors, CEO appointment
The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.
Huang is managing partner of Kleiner Perkins Caufield Byers China and general partner of KPCB China Fund II, which invested in EntreMed's previously announced registered direct financing that closed in March 2013. Prior to Kleiner Perkins, he served as managing partner at Vivo Ventures, a venture capital firm specializing in life science investments. Huang has over 20 years of experience in the pharmaceutical and biopharmaceutical industry. During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva, Tularik, GlaxoSmithKline, Bristol-Myers Squibb and ALZA.
Wu is co-founder and CEO of Crown Bioscience, a drug discovery and preclinical research organization in the oncology sector with over 300 employees. Before co-founding Crown Bioscience, Wu was chief business officer of Starvax International, a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the head of Asian operations with Burrill & Company, a life science venture capital and merchant bank. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning.
EntreMed also announced that Ken K. Ren, Ph.D. has been appointed CEO, after having completed his one-year term as interim CEO. In addition, Mark C. M. Randall has resigned from its board of directors.